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ABSTRACT 
 
Alzheimer’s disease is a neurodegenerative disorder that occurs most commonly 
in the elderly. The formation of amyloid plaques and neurofibrillary tangles affects 
the brain tissue, causing mental deficits ranging in severity from memory loss to 
incontinence and feeding problems. Currently, the only approved treatments are 
designed to treat the symptoms of the disease, rather than prevention or slowing 
the progression. Yet, over the course of the last few decades, researchers have 
sought new ways of treating the condition.  One such drug with promising effects 
is the cholesterol lowering statin medication. Yet the efficacy shown in the 
laboratory has not translated to clinical trials to treat AD patients. Therefore, this 
study analyzed various important biomedical and clinical studies in the literature 
to elucidate why this disparity exists.  On examination of biomedical studies, 
there was a wide range of support for statins due to its many pleiotropic effects. 
This drug was shown to be permeable through the blood brain barrier, helping to 
reverse the damage caused by amyloid plaque formation in brain vessel walls. 
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Other studies showed the link between high cholesterol and AD by analyzing the 
effects of memory deficits in mice while they attempted various tasks. They used 
analogs to simulate the disease and found that statins helped delay or reverse 
some of these changes. On examination of clinical studies, the majority of 
studies could not find a statistically significant correlation between statin use and 
neuroprotection against AD. Those that did find a positive correlation needed 
further study to account for any confounding variables. After examination of these 
papers it became clear that the disparity between the two realms of study was 
due to the design of the experiments themselves. The biomedical studies 
focused on various effects of statins rather than on how the mechanisms of 
action directly affected AD progression. As of yet not all of the pleiotropic effects 
have been examined and definitely not within the context of how they effect and 
complement one another. Thus clinical trials trying to integrate this information 
have been very discouraging and the designs of these studies, both prospective 
trials and epidemiological studies further complicate the answers sought. They all 
varied in the age groups they examined, how early treatment was initiated, which 
statin was used, and how other confounding variables (such as 
sociodemographics and smoking) were accounted for. After analyzing the 
literature, it is in our opinion that statins play a protective role if initiated much 
earlier than the first clinical signs. However the only way to know how it 
biochemically may help AD patients is through further study. So, it is our 
 v 
recommendation for more in depth study on the pleiotropic effects of statins on 
AD, before further clinical intervention occurs.  
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INTRODUCTION 
 
Alzheimer’s Disease 
 Alzheimer’s disease (AD) is a neurodegenerative dementia disorder 
caused by neurofibrillary tangles (NFT) within the cell and amyloid beta peptides 
(Aβ) extracellular to the cell. It occurs in the cerebral cortex, and more specifically 
within the limbic system 1. Alzheimer’s is a disease of a progressive nature 
affecting the elderly and causing loss of cognition and memory. Accumulation of 
Aβ peptides leads to plaques within the extracellular environment, which cause 
neurotoxicity and neurodegeneration2. Alzheimer’s affects up to 5 million 
Americans and that total is expected to climb upwards to 13 million by 2030 3. 
Thus as medicine helps us live longer and longer, conditions such as 
Alzheimer’s, which afflicts the elderly, will only become more common among 
geriatric patients.  
Statins: A Secondary Role 
 Statins, a class of drug used to treat that high cholesterol levels, are 
lipophilic molecules that can more easily cross the blood brain barrier (BBB) and 
have their effects in the central nervous system (CNS) than other drugs that are 
hydrophilic, which have a tougher time entering the CNS. These molecules work 
by inhibiting hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, which is 
a rate-limiting enzyme in the endogenous cholesterol pathway 4. By inhibiting this 
enzyme, endogenous cholesterol production is lowered which promotes LDL 
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uptake by hepatic cells, effectively lowering plasma LDL levels and treating 
hypercholesterolemia very effectively 4. 
A second, possibly even more beneficial role of this already FDA 
approved drug, would be in the treatment of a wide range of neurodegenerative 
disorders.  Evidence has shown that statins able to cross the BBB can directly 
stimulate and up regulate endothelial nitric oxide (NO) synthase (eNOS) as well 
as indirectly stimulate its production through the actions of the phosphatidyl-
inositol-3-kinase/protein kinase Akt (PI3K/Akt) pathway 2. The production of NO 
subsequent to eNOS activation causes a massive increase in cerebral blood 
flow, which is thought to play a vital role in the process of learning and memory.  
However, changes in structural integrity that occur in the basement 
membrane and the associated extracellular matrix (ECM) due to AD alter the 
normal BBB function of the vessels supplying the CNS.  This causes a vascular 
pathology that affects the brain and is made worse by the Aβ plaque 
accumulation in the ECM, which affects the astrocytes that support neurons. 
These astrocytes are also part of the BBB and thus play a structural role as well 
as a regulatory role in preventing cerebral ischemia 1. Thus in this way statins 
can help to levy the neurotoxicity caused by Alzheimer’s disease byproducts and 
possibly promote advanced learning and cognition or at least plateau the 
cerebellar degeneration at that stage of development (Figure 1) 4. 
This study will first give a background introduction to Alzheimer’s disease, 
including its pathology and current treatment, and will follow with details on the 
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statin family of drugs and their affects in the human body. Next this study will 
compare various biomedical studies supporting statin’s efficacy in treating AD 
against clinical trials, attempting to show a correlation between the two. Finally, 
we will analyze this data and discuss why the disparity between preclinical and 
clinical studies exists.  
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Figure 1. A Schematic Diagram of the Proposed Neuroprotective 
Effects of Statins in AD. Statins, which are known for their ability to lower 
cholesterol levels by acting on apolipoproteins (ApoE here) to affect fat 
metabolism. This in turn affects the amyloid beta plaque formation, which is 
a major player in Alzheimer disease degeneration due to the body’s 
inflammatory response and subsequent neurotoxity. Statins also lower 
levels of activators in the AD pathway. This study aims to elucidate 
possible reasons why the proposed neuroprotective effect doesn’t extend 
to clinical trials. (Figure taken from Wang, et. al, 2010). 
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BACKGROUND 
 
Alzheimer’s Disease 
History 
The progressive deterioration of mental faculties, otherwise known as 
dementia, has long been a part of human history, dating all the way back to 2000 
BC with the ancient Egyptians. Prominent ancient Greek philosophers, such as 
Cicero and Plato, later debated whether senile dementia was a normal part of the 
aging process. Then during the Hellenistic Empire, writers Galen and Celsus 
described acute psychiatric disorders as a reversible delirium, whilst dementia 
was further defined as a permanent impairment of cognition5. Finally, in the 18th 
century, the term dementia was commonly used and put into French law, giving it 
both clinical and legal ramifications6. 
Article 10 of the Napoleonic Code 1808: There is no crime when 
the accused is in a state of dementia at the time of the alleged act. 
 
 It was in 1910 that Emil Kraepelin, the father of modern scientific 
psychiatry, first coined the term Alzheimer’s disease in his Textbook of 
Psychiatry, based on Alois Alzheimer’s 1907 paper detailing his discovery of 
“new pathological markers for the very old concept of dementia”. Alzheimer’s 
discovery of the biological markers was not the first however, and was previously 
written about by Fuller 5 months prior, as well as by Beljahow in 1889 and many 
others6. The markers he “discovered” were neurofibrillary tangles and senile 
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plaques in an autopsied brain that belonged to Auguste Deter; a 51-year old 
delusional, disoriented, and forgetful woman 7.  For 5 years, from 1901-1906, 
Alzheimer developed a relationship with Auguste D. by using his skills in clinical 
interviews to gain her trust through conversation 8. Upon her death and 
examination of her brain, he noted that these markers were present in an atypical 
form of senile dementia, which Kraepelin later expounded upon to define AD as a 
presenile form of dementia that “sometimes starts already around the age of 
40”6.  
 Afterwards till 1975, Alzheimer’s disease was seen as a relatively rare 
condition, and only 42 papers had been written about the disease. Then an 
exponential rise in AD research occurred, due to attrition of various forms of 
previously classified and then reclassified dementias and due to AD being 
formally recognized by the medical community as having the same clinical and 
pathological manifestations as senile dementia, though with different etiologies. 
This was due to the heterogeneous progression of Alzheimer’s disease, but 
through years of research it was found that the underlying process consisted of 
increased deposition of Aβ protein. 5 
 Thus through a long arduous journey, Alzheimer’s disease has become 
one of the most studied disorders of the past twenty years, and has led to greater 
understanding of the condition and how to treat it clinically. 
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Signs, Symptoms, and Diagnosis 
Alzheimer’s disease is the most common subtype of dementia, accounting 
for about 60% of all cases9.  It is the most common disease of aging among the 
elderly and hence the focus of much research in the last quarter century. As of 
2010, there is estimated to be 35.6 million people across the world living with 
dementia. The cost of providing treatment for the condition costs $600 billion 
annually and is expected to double by 2030 and then quadruple by 205010.  
Nationally, 5.3 million Americans have AD, or 1 in 8 adults over the age of 65, at 
an annual cost of $172 billion 7.  
Most of these cases are sporadic and random, increasing in frequency 
with age and among women, but 5-10% of AD cases are familial in nature11. For 
these patients, having certain genes such as the APOE ε4 allele make them 
more predisposed to acquiring AD. Alzheimer’s disease has been positively 
correlated with a wide variety of risk factors, including hypercholesterolemia, 
atherosclerosis, hypertension, and diabetes mellitus (Table 1). According to one 
meta-analysis, the prevalence of AD consistently doubled every 5.1 years after 
age 60 12. This helps support the strong relationship between age and AD due to 
the pathophysiological changes that occur in older adults (see next section).  
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 Table 1 Alzheimer’s Risk Factors(adapted from 13) 
 
I 
 
It is because of these changes that better detection methods are needed. 
The need is not only to identify molecular biomarkers to diagnose AD but also to 
predict future cognitive decline before it becomes clinically apparent. This is 
Sociodemographic 
 Age: increasing age 
 Sex: no consistent evidence  
 National and ethnic profile: some evidence of regional variations 
Familial and genetic factors 
 Family history: 3.5-fold increase in risk when a first degree relative is 
affected 
 Diseases causing mutations: on chromosomes 1, 14, and 21 
 ApoE genotype 
 Down’s syndrome: everyone eventually develops the neuropathological 
features of Alzheimer’s disease 
 Premorbid cognitive reserves: longer education and higher intelligence 
are protective 
Medical history and treatments 
 Head injuries: anti-inflammatory drugs are associated with a reduction 
in risk 
 Oestrogen replacement: no consistent evidence 
 Vascular risk factors: hypertension, diabetes, homocysteine, and 
cholesterol are all implicated 
 Depression: associated with Alzheimer’s disease 
 Herpes simplex: a risk factor, possibly mediated by the presence of 
ApoE e4  
Habits 
 Alcohol: drinking wine is protective 
 Smoking: no consistent evidence 
 Diet: no consistent evidence (including for aluminium)  
 Occupational and recreation factors: no consistent evidence 
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because the first symptom is memory loss, which family members and casual 
friends may attribute to old age, failing to recognize it for what it really is. 
Early detection before cognitive decline happens, during the mild cognitive 
impairment (MCI) phase, can greatly help patients by facilitating early drug 
administration, obtaining social support, and treating coexisting problems that 
may occur like vascular disease6. More specifically, the neurobiological 
advantage is that there is a smaller load of amyloid and hyperphosphorylated 
tau. Therefore with current and new therapies targeting these proteins before 
symptoms become clinically apparent, they may be able to reduce or eliminate 
the secondary effects these proteins have on the body, including inflammation, 
oxidation, excitotoxicity, and apoptosis 14.  
It is extremely beneficial to diagnose early, as the MCI stage may remain 
stable for several years before further deterioration occurs. During this period 
(Figure 2), although the patient may present with symptoms of memory loss, 
there will be little notable impairment on daily life. Yet as the cognitive deficit 
progresses (those with MCI are 15 times more likely to develop dementia at 
follow up) a loss of semantic memory (general knowledge) and implicit memory 
(experiences that affect present actions) can hinder day-to-day functionality13. 
Moreover, at this point the efficacy of any treatment is far below peak levels. 
In order to diagnose Alzheimer’s disease, a variety of criteria must be met. 
These include cognitive function tests, clinical examination with a focus on 
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vascular and neurological signs as well as taking a full history with a close family 
member or guardian, and histopathological confirmation 15. 
 
 
 
 
 
Figure 2. Symptom Progression in Alzheimer’s disease. (Figure adapted 
from Burns and Illiffe, 2009) The Mini-Mental State Examination is a 30-
question exam used to screen for cognitive impairment and can be used 
throughout the course of a patient’s treatment to objectively record disease 
progression and the response to therapy. 
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Yet before trying to diagnose AD, the medical team must rule out other 
conditions with similar symptoms that mimic dementia. These include a wide 
range of disorders, including Parkinson’s disease, brain tumors, structural brain 
lesions, as well as disorders like thyroid disease, and vitamin B12 deficiency7. 
The clinical examination is very useful in this regard. Since AD is difficult to 
detect (as there is no simple test for the condition), ruling out these differential 
diagnoses as the cause of the patient’s symptoms can help physicians find the 
root of the problem (Figure 3). Once these diagnoses are ruled out, and once the 
condition presents clinically as an “insidious impairment of higher intellectual 
function with alterations in mood and behavior”11, a clinical diagnosis of probable 
AD can be made.  
 Neuropsychological evaluations, such as the Mini-Mental State 
Examination (MMSE), are also extremely important in assessing which cognitive 
processes have been affected. Tests can be used to measure memory, language 
skills, attention, orientation to place and time, social function, and problem-
solving skills 15. Since the course of the disease varies from individual to 
individual, these tests allow a subject to be compared to a control group to 
monitor changes in mental capacity. More importantly, as the disease progresses 
these evaluations can help determine what stage of the disease they 
concurrently fall in. One such staging system is the Clinical Dementia Rating 
(CDR)7. 
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Figure 3 Ruling out conditions that mimic Alzheimer’s disease (taken from  
Alzheimer’s Association) 
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 The CDR is on a scale from 0 to 3, derived from interviews with the patient 
and with an informant. It is then used in conjunction with physical examination by 
the clinician to determine the severity of dementia present. It corresponds to 
different points in the progression of the disease.  
The early stage of mild AD lasts about 2-5 years and the patient is 
independent in taking care of themselves with little to no effect on daily life. The 
second moderate stage lasts 2-4 years, affects long term memory as well as 
much impairment in normal daily tasks. They may require more assistance and 
help for even basic grooming needs. The severe stage of AD is marked by a total 
loss of independence and having to rely completely on a caregiver, as bodily 
functions such as swallowing and control of bowel movements fail them.7 
Finally a brain biopsy or cerebrospinal fluid (CSF) can be used to confirm 
the AD diagnosis. These are used to check for abnormal CSF biomarkers 
indicative of Alzheimer’s.  Labs can also take blood samples to determine if an 
individual carries a proven AD autosomal dominant mutation within their family 
that could put them at higher risk for the disease. The use of an MRI or PET scan 
can also help distinguish supportive features16,17. For example, with an MRI the 
presence of medial temporal lobe (MTL) atrophy can be seen, which is common 
in AD (71-96%) and with a PET scan reduced glucose metabolic activity 
(diagnostic criteria for AD) and protein aggregates of amyloid and tau in the brain 
can be measured 14. Together, these evaluations and tests help physicians 
properly diagnose AD.  
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Pathophysiology 
The neuropathological effects of Alzheimer’s disease are so visible they 
can be seen in a gross section as well as a microscopic section.  As shown in 
Figure 4, there is a very visible atrophy of the brain, with a positive correlation 
the greater the severity of the disease.  This neuronal loss and reduced synaptic 
density is responsible for the loss of memory and later normal daily function18. 
Microscopically, AD has a very well defined hallmark profile that was seen by 
Figure 4. Visual assessment of the medial temporal lobe 
atrophy (Taken from UC Berkeley CSUA). 
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Alois Alzheimer and his colleagues back at the start of the 20th century. The main 
features are extracellular senile plaques and intracellular neurofibrillary triangles. 
Once Aβ, a 40-42 amino acid aggregated polypeptide, was identified as 
the main constituent of these senile plaques19 further genetic studies in mice 
showed that mutations in the amyloid precursor protein (APP) (from which Aβ is 
derived) caused an accumulation of Aβ that lead to early-onset familial 
Alzheimer’s disease (fAD). This helped formulate the Amyloid cascade 
hypothesis (Figure 5), which states that either through a familial missense 
mutation or sporadic AD, deposition of amyloid-β occurs which is the initial 
insult20. Through the increased Aβ levels, an inflammatory response occurs with 
more progressive oxidative injury that causes hyperphosphorylation of NFTs, 
which causes cell death and presents clinically as dementia 21. 
 The two forms of AD are early onset fAD and sporadic AD22. Although the 
final point in both of these conditions is the accumulation of amyloid-β plaques in 
the extracellular environment, they reach this by very different means. In the 
familial form (less than 10% of AD cases), mutations in 3 genes can account for 
the formation of Aβ: Amyloid precursor protein, presenilin 1 (PSEN1), and 
presenilin 2 (PSEN2)20. This leads to a disposition to develop AD, through a 
lifelong increase in Aβ production above normal levels.  
Sporadic Alzheimer’s disease is the result of a variety of risk factors 
discussed earlier in this paper. Perhaps the most relevant risks, including aging, 
are hypercholesterolemia and hypertension. In sporadic AD, it is a failure of 
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clearance mechanisms that cause the buildup of insoluble senile plaques seen in 
the AD brain. Aβ is also found in soluble forms throughout life, and serves many 
physiological functions, but as we age, our clearance of this peptide decreases 
and causes amyloid buildup on the walls of arteries (especially the meningeal 
arteries), which is called cerebral amyloid angiopathy (CAA)23. CAA causes 
intracerebral hemorrhage and ischemia, causing a vascular pathology 12. Failure 
to remove Aβ causes a 100-1000 fold toxic accumulation 24and starts a series of 
detrimental changes in the brain. 
The formation of amyloid plaques starts with its precursor protein APP. 
APP is a membrane protein that is cleaved by enzymes. Normally, this metabolic 
activity is caused by α-secretase and then further broken down by γ-secretase25. 
Because of α-secretase’s cleavage site on APP, proteolytic cleavage by β-
secretase is hindered. In the amyloidic pathway, β-secretase cleaves APP 
followed by γ-secretase which causes the formation of Aβ as seen in Figure 618. 
These polypeptides are prone to aggregate into insoluble forms. The 
conformations inside these plaques include fibrils, oligomers, and a β-sheet 
formation26. Accumulation of these structures causes an inflammatory response, 
and can be seen by the surrounding swollen and degenerating axons and 
dendrites, gliosis, and a proliferation of an immune response by an increased 
number of microglia and astrocytes 7. 
Intracellularly, these changes lead to NFT in the cell bodies of the 
neuron27. Normally, tau is a protein used to create microtubules (MT) in the axon 
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compartment, which serve as the cytoskeleton as well as function to transport 
cellular contents.  Phosphorylated tau dissociates from MT and becomes an 
insoluble “tangle” 18. This causes a weakening of neural network that ultimately 
leads to the neuronal death seen in gross sections.  
 
 
Figure 5 Amyloid Cascade Hypothesis (Adapted from Neurokos 2008) 
Shown is the Amyloid Cascade Hypothesis, a widely accepted theory of the 
causes behind how dementia and AD occur molecularly. 
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Figure 6. Proteolytic Cleavage of APP (adapted from 28) 
Cleavage of APP is determined by the category of enzyme and its specific 
cleavage site.  
 
 
 
Current Treatments 
 Currently, drugs prescribed for Alzheimer’s disease do not prevent or treat 
the condition effectively. Rather the treatments work to fix the neurotransmitter 
imbalance in the brain 9. Therefore the pharmacotherapeutic approach is used to 
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treat symptoms and not the underlying problem of the disease. The 4 FDA 
approved drug treatments for AD are three cholinesterase inhibitors (ChEI), 
Donepezil, Rivastigmine, and Galantamine, and a Glutamatergic partial 
antagonist, Memantine, used for moderate to severe stages of AD 13. 
 Due to the disease progression, AD patients have a reduced amount of 
choline acetyl transferase, an enzyme that is used in the synthesis of 
acetylcholine (ACh). ACh is a very important neurotransmitter used to relay 
signals between neurons. Because of this decreased production of ACh, any 
degradation of the NT by cholinesterases would further reduce the available 
supply and cause a marked diminishment of signal transduction. Therefore, 
these ChEI work to inhibit these degrading enzymes and thus prolong the 
efficacy of ACh in the synaptic cleft 29. The implementation of treatment is vital 
and the earlier it is started the greater the results. As discussed earlier in this 
paper, this is why newer and more indicative biomarkers at early stages of the 
disease are needed. They not only could elucidate new ways of treating the 
disease, but also a faster implementation of current accepted therapies 10. In a 
52-week study done by Farlow et al in 2000, researchers studied the efficacy of 
rivastigmine in patients with mild to moderate AD30. They found that patients that 
started treatment 6 months earlier had a much higher level of preserved cognitive 
function as opposed to those who waited to initiate treatment and instead had 
cognitive decline occur during the same study period.   
 20 
 The drug Memantine is an option used for patients in the later more 
severe stages of AD. This drug targets the glutamatergic system, rather than 
cholinesterase, and thus has a different mechanism of action. The drug acts as 
an N-methyl-D-aspartate (NMDA) receptor antagonist29. The primary NT for this 
receptor is glutamate, which is the primary excitatory NT for cortical neurons. 
This receptor is one of the most studied, as it plays a crucial role in learning and 
memory in the hippocampus. While the role of ChEIs are to prolong the exposure 
of ACh, Memantine works as a neuroprotectant and protects the brain against 
excessive receptor stimulation 9. This is induced by ischemia, which is a 
downstream effect caused by amyloidosis, and thus leads to excitotoxicity.  
Memantine is noncompetitive and works to not only reduce toxicity, but also 
helps to return normal neuronal function, leading to a restoration of long-term 
potentiation which is essential in learning and memory. Analysis has shown that 
within 24 weeks of treatment, a significant improvement in memory, language, 
and praxis was observed as well as less cognitive decline compared to the 
control group 31. 
 Current therapies are used only when symptoms arise rather than used in 
prevention/treatment and thus fail to have an optimal effect on AD patients. 
There are many clinical trials and biomedical studies being done on a multitude 
of proposed drugs to address AD, hoping to find a neuroprotectant to prevent 
further damage or even possibly reverse the damage. However, it will be many 
more years before FDA approval for any such drug is acquired.   
 21 
 
Statins 
Primary Role: Cholesterol Reduction 
 According to the Centers for Disease Control and Prevention (CDC) , 71 
million American adults have high levels of low density lipoprotein (LDL), 
commonly known as “bad” cholesterol. Yet even though a third of all American 
adults have these levels, only 1 out of every 3 people have the condition under 
control and less than half of them get treatment for this problem. Having high 
levels of cholesterol significantly increases your chances of developing heart 
disease which is the single greatest cause of death in the United States. More 
deaths can be attributed to heart disease than cancer (second leading cause of 
death) and it accounts for more deaths than chronic lower respiratory diseases, 
stroke, accidents, AD, and diabetes combined (causes 3-7) 32 
 A high level of cholesterol, otherwise known as hypercholesterolemia, is 
the main cause of atherosclerosis, a hardening of the arteries. When levels of 
this lipoprotein are elevated, they overtime create atheroma plaques within the 
walls of the arteries33. Initially they cause many physiological effects, including 
causing endothelial cell injury and thus making the walls of the arteries more 
permeable. In addition they cause monocyte migration and activation to 
macrophages. The LDL that crosses the vessel wall will then be oxidatively 
modified by reactive oxygen species 11. This new form of LDL is much more 
susceptible to uptake by macrophages through scavenger receptors and help 
 22 
form foam cells.  This is because once inside the macrophage, it can’t be 
processed. As these cells build up in the tunica intima of the vessel wall, they can 
burst and release the oxidized LDL they had been storing (Figure 7). This 
creates a further amplification of the immune response, causing a greater 
migration of monocytes to the area, conversion to macrophages within the vessel, 
and formation of more foam cells11. The accumulations affect the integrity of the 
vessel wall, and result in occlusion of blood flow as well as infarctions in smaller 
arteries and even a cerebrovascular stroke if pieces fragment off 34. 
 Although high levels leave the individual at risk of developing heart 
disease, LDL is not without its own purpose. The common phrase for LDL, “bad 
cholesterol”, is a misnomer that implies it has no significant physiological effects. 
However, LDL’s role is the main carrier of cholesterol for the body, essential for 
supplying it to the various cells that need certain levels of it within the plasma 
membrane or for steroid synthesis to function properly23. It is when LDL levels 
become elevated due to environmental factors such as physical inactivity and 
poor diet as well as a dysfunction in its circulation and/or production due to 
genetics that it becomes a problem35. 
 Familial hypercholesterolemia (FH) is an autosomal dominant disorder 
that causes elevated levels of LDL cholesterol due to either a mutation in the LDL 
receptor, which is responsible for removing LDL from the bloodstream, or 
apolipoprotein B (ApoB), which is a part of the LDL structure. This disorder 
causes cardiovascular disease at an earlier age than those with non-familial 
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hypercholesterolemia. It is commonly observed clinically with the accumulation of 
cholesterol in the skin, called xanthomas, or depositions within the eyes. 36 
 
 
 
 
Fi
gu
re
 7
. R
el
at
io
ns
hi
ps
 b
et
w
ee
n 
C
ho
le
st
er
ol
 a
nd
 A
th
er
om
at
ou
s 
Le
si
on
s 
(a
da
pt
ed
 fr
om
 37
) 
 
 24 
Cholesterol Pathway 
 In response to high cholesterol, lipid-lowering drugs have been created to 
help lower levels of LDL circulating in our bloodstream. The most commonly 
prescribed and used medication is the statin family (Figure 8). They are 
extremely effective by disrupting the metabolic synthesis responsible for the 
creation of cholesterol, thus limiting the total amount of the cholesterol available 
for transport through the body 33. 
 In addition to the cholesterol we attain through our diet, some of the 
cholesterol is synthesized in our liver and other organs. The cycle starts with 
movement of acetyl-CoA (coenzyme A) derived from oxidation within the 
mitochondria to the cytosol 38. Here it follows a multistep process to become the 
27 carbon molecule. The acetyl-CoA is converted to HMG-CoA (3-hydroxy-3-
methyl-glutaryl-CoA) by HMG-CoA synthase and then converted to mevalonate 
via HMG-CoA reductase (HMGR) 39. This is the rate-limiting step in cholesterol 
biosynthesis and is the point of physiological regulation for the pathway. The 
body maintains cholesterol at steady levels by direct feedback inhibition of 
HMGR by cholesterol and its subsequent proteolytic degradation.  The 
mechanism of action of statins also works by inhibition of HMG-CoA reductase. 
They reversibly and competitively inhibit the enzyme causing a lowering of 
cholesterol production34. 
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Figure 8. Chemical Structures of Statin Family used in Treatment of High 
Cholesterol (adapted from 34). They come from both fungal fermentation and 
synthetic derivation. The differences in structure between the molecules allow 
them to be hydrophilic or hydrophobic. They also have different half-life values 
within the body, with a range of 1 to 3 hours, except for atorvastatin with a 14 
hour half-life and rosuvastatin with a 19 hour half-life. The lactone lipophilic forms 
(simvastatin and lovastatin) have been shown to be able to pass the BBB40. 
HMG-CoA structure has been added to demonstrate how statins have a similar 
analog structure 41. 
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Efficacy of Treatment 
Molecular Structure 
The use of statins in treating hyperlipidemia and dyslipidemia has proven 
to be an enormous pharmaceutical advantage to physicians and their patients. 
According to Hovingh et al, “There is now uniform consensus that lipid-lowering 
drug therapy is the cornerstone of management in adults.” This is a sentiment 
that is widely accepted in the vast majority of publications. By inhibiting the HMG-
CoA reductase42, statins have been shown to reduce LDL cholesterol levels by 
50-60% at their maximum doses, as well as help those with FH increase their 
LDLR activity (shown to lower risk of coronary heart disease by 80% when 
started early on in childhood 36. 
 
Figure 9 Statin therapy and its effects on contributing factors to 
Atherosclerosis (adapted from 33) 
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Noncardiovascular Benefits 
Statins have a wide range of pleiotropic effects in addition to their cholesterol 
lowering potential, making them a widely studied drug to treat a variety of 
conditions. They have antioxidant effects, anti-inflammatory properties, 
improvement of endothelial function via NO, anticarcinogenic properties, 
anticoagulant effects, etc43. Some of these are through mechanisms of action 
independent from the mevalonate pathway. Others are consequences of the 
lowering of mevalonate concentrations, such as its effect on isoprenylation. 
Isoprenoids are creating in the intermediary steps of cholesterol synthesis and 
exert many of their own effects on our physiology. For example, farnesyl 
pyrophosphate (FPP) created in the seventh step is also required for proper 
subcellular localization and trafficking, as well as the substrate for Coenzyme Q. 
Reduction of FPP for coenzyme Q is believed to account for some of statin’s side 
effects 41. 
 Statins are important for the study of this paper for their purported 
neuroprotective effects against neurodegenerative disorders of the central 
nervous system. In particular, how their cholesterol lowering effects can affect 
brain chemistry and whether or not it could be a successful treatment to prevent 
Alzheimer’s disease. 
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Specific Aims/Objectives 
 The current available literature assessing whether or not statins are 
effective at ameliorating the effects of Alzheimer’s disease are inconclusive. 
While some papers will state the outstanding effects one type of statin will have 
in treating dementia, another type of statin will have no effect or even an adverse 
effect upon the model.  The use of different statins from the family along with 
patients in different stages of the degenerative process allows studies to have 
obvious differing results. More importantly, we attempt to answer whether the 
disconnect between clinical and biomedical studies is due to different target 
goals or a fundamental flaw in the way studies are designed.  
 The goal of this study is to provide enough data to help understand why 
statins have differing effects on memory and cognition. This study will aim to: 
(1) Discover if the results seen in in-vivo cell cultures of hippocampal cells 
and mice/rat models of Alzheimer’s disease translate to clinical trials. 
 
We hope our study will be able to provide sufficient in depth analysis of 
statins to determine why such a potent drug in the lab has been shown to have 
little to no effect in trial. Using these results we hope other labs may be able to 
better quantify their results due to confounding variables. 
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LITERATURE REVIEW 
 
Biomedical Studies 
In this section, lab studies on the effect statins have on Alzheimer’s 
disease will be reviewed, focusing on what questions they attempted to explore, 
what experimental design was used, and what results they found. By reporting 
this data, we hope to reach a comprehensive conclusion about how differences 
between the studies affect their outcomes during our own analysis in the 
Discussion section. As the research on this topic has been extensive and has 
changed very much, this paper will mostly analyze recent papers within the last 
few years. 
In Kandiah and Feldman, the link between cholesterol and AD 
pathogenesis is given as to why statins may have a therapeutic effect in treating 
dementia. High cholesterol levels lead to an accumulation in the lipid rafts of the 
neuron’s membrane, where APP cleavage occurs. Instead of alpha-secretase 
acting on APP to form soluble amyloid that is easily cleared, there is a greater 
action of beta- and gamma- secretases, which causes more insoluble Aβ to 
aggregate outside the cell that further leads to a hyperphosphorylation of tau 
within the neuron. In another pathway, cholesterol acts through its presence in 
atherosclerotic plaques. As these plaques form on the blood supply of the brain, 
they can cause cerebral ischemia and stroke. Ischemia is associated with an up-
regulation in APP and damage to the BBB45, which impairs clearance of soluble 
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APP. As discussed earlier in this paper, CAA and Aβ accumulation in vessel 
walls may also play a role46. This is due to the high prevalence of APOE4 allele 
in AD (40-60%), since it involves the APOE-cholesterol-lipoprotein complex that 
causes vascular deposition of Aβ as seen in animal models.47 
The link between high cholesterol and accumulation of amyloid particles 
lead to Parle and Singh’s paper testing the effects of Atorvastatin and 
Simvastatin in reversing memory deficits in rats. They used Alprazolam and 
Scopolamine to induce anterograde amnesia, as well as a high fat diet for 90 
days. To test the effects of the drugs, they used two behavioral models. The first 
was an Elevated Plus-Maze apparatus to study memory acquisition and retention. 
Here they measure transfer latency, described as the amount of time it takes the 
rat to move into one of the enclosed “arms” of the maze with its four legs. The rat 
was allowed to explore the maze and tested 24 hours later. 
The second model was the Morris Water Maze. Here a circular water tank 
is filled with water that is made opaque with a dye. The tank is split into four 
quadrants, with a center-hidden platform in quadrant 4.  After showing the rat the 
hidden platform on the first day, its escape latency time to find the hidden 
platform was measured, as well as the amount of time spent within the target 
quadrant to find the platform compared to other areas. The starting point was 
varied so that location of the platform could be used to assess learning.2 
Results showed that Atorvastatin and Simvastatin given before the 
elevated plus-maze trial significantly reduced the induced anterograde amnesia 
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caused by Alprazolam and Scopolamine (which models memory deficits but not 
the pathology of AD) when administered before the trial (p<0.05), as well as 
significantly reduced the retrograde amnesia caused when the drugs were 
injected after training on the first day. High fat diet rats exposed to a 15-day 
treatment with Atorvastatin or Simvastatin also showed a reversal of memory 
deficits.2 
 In the water maze trial, pretreatment of induced-anterograde amnesia rats 
with Atorvastatin or Simvastatin showed a significant decrease in escape latency 
time as well as a significant increase in the time spent within the target quadrant. 
Also, when administered on the last day of the trial (day 5), the drugs significantly 
reduced the retrograde amnesia caused by Alprazolam, high fat diet, and 
Scopolamine as well. In high fat diet rats, treatment with statins for 15 days also 
produced a marked fall in the total cholesterol levels, although treatment for 1,2 
or 5 days showed no significant changes.2 
A study by Ghodke et al recently expanded upon this cholesterol 
hypothesis 48of how exactly statins exert their effect on the brain, and whether or 
not a link can be made between cholesterol and memory function. Here they 
analyzed the long-term statin treatment in mice using the same elevated plus 
maze test and a step down passive avoidance test (mice on a platform who step 
down are shocked during training and in subsequent trials, the longer it takes for 
them to step down (latency) the greater the retention)49. They also used 
pravastatin, which is hydrophilic, and simvastatin, which is lipophilic, to assess 
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which works better by measuring cholesterol and AChE levels41. Instead of 
inducing amnesia, they measured the short-term (15 days) and long-term (120 
days) effects of statins against a control and a high cholesterol diet (120 days) 
group. The long-term treatment of the statins showed a significant improvement 
in memory retention in both models, but the short-term treatment improvement 
was within the standard deviation of error. The high cholesterol diet caused a 
decline in cognitive function50, which was also seen in the previous study49. High 
levels of plasma cholesterol have been linked to increased prevalence of AD51. 
This study also measured levels of blood cholesterol and brain cholesterol, 
to assess if being lipophilic was important. They found that although both 
simvastatin and pravastatin reduced blood cholesterol levels, only long-term 
simvastatin treatment effectively reduced brain cholesterol levels. This was 
expected, as pravastatin’s hydrophilic nature would prevent it from crossing the 
BBB. Yet, elevated brain AChE levels with the high cholesterol diet mice were 
actually significantly reduced with simvastatin and pravastatin treatment, 
regardless of if it was for the short duration or long duration. As acetylcholine 
levels are crucial for long-term potentiation for learning and memory, these lower 
levels of AChE may potentially be another pleiotropic effect of statin therapy.49 
In 2012, Tong et al. reported on an experiment on AD-model mice to 
assess a variety of questions. Foremost, they wanted to assess if early treatment 
of statins in early old age rather than late age would be associated with a lower 
incidence of AD and if statins helped reduced amyloidosis or if it was a 
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pleiotropic effect that caused retention of memory and learning52. They used a 6-
month-old adult mice model and a 12-month-old mice model, expressing a 
mutation of the APP gene. The mice were treated with simvastatin for 3 months 
(6 month old mice) or 6 months (12 month old mice), and the water maze test 
was administered to test their learning retention. Afterwards, flurodeoxyglucose-
PET was used to examine cerebral glucose uptake following whisker stimulation 
and after death they were used for a wide variety of measurements, including 
amyloid levels, cerebrovascular reactivity, and anatomical staining. 52 
Simvastatin helped restore cerebrovascular reactivity in the mice. The 
cerebral arteries from the APP mice were dilated due to reactive oxygen species 
that caused oxidative stress as well as a dysfunctional potassium channel in the 
vessel walls. Simvastatin helped normalize the levels of these oxidants and 
restore channel function, causing a subsequent increase of NO bioavailability, 
restoring vessel reactivity. It was also linked to higher levels of glucose 
metabolism in PET scan, compared to the model mice in the somatosensory 
cortex following whisker stimulation (Figure 10). Simvastatin also helped to 
preserve learning and memory in the adult mice, but not the aged 12-month mice. 
In this Morris water maze, simvastatin helped increase learning and memory in a 
reproducible fashion, but had little effect on the older APP mice, providing 
evidence for the need to assess at which pathological stage of the disease 
progression to administer statin treatment.52 
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Lastly, and probably most importantly for our own study, Simvastatin did 
not help reduce the amyloidosis caused by AD. Using Western Blot analysis and 
ELISA, no significant reduction in amyloid levels, soluble or plaque, was seen 
with Simvastatin therapy compared to the APP mice. These results point towards 
a different pathway for simvastatin therapy in regards to Alzheimer’s disease, 
different from its prescribed effects in the body34. It’s antioxidant and anti-
inflammatory properties help the brain restore cognitive function by restoring the 
cerebrovascular impairments, as well as increasing glucose metabolism53. 
Together these findings point towards the many protective mechanisms of 
simvastatin against cognitive impairment, rather than a restorative function, since 
amyloid production or removal was not significantly altered.52 
 
 
Figure 10 Effect of Simvastatin (SV) on Brain Glucose Metabolism (adapted 
from Tong et al50). This figure shows the results of Fluorodeoxyglucose-Positron 
Emission Tomography. This was taken after the Morris water maze, in response 
to whisker stimulation. The somatosensory cortex was measured for glucose 
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delivery. In APP mice treated with SV, there was a significant restoration of 
glucose metabolism. 
 
 These results are in stark contrast to other papers that claim a reduction in 
Aβ plaques. These studies gave statins to mice and found their Aβ levels to be 
lower than controls however upon statin removal the Aβ levels returned to normal 
levels3,54,55. And yet other studies, such as Li et al, interpreted their own 
behavioral tests and biochemical analyses (after Simvastatin treatment) and 
found that Simvastatin enhanced cognition independently of amyloid removal. 
What they found was that it actually increased levels of nitric oxide and protein 
kinase B/Akt in AD mouse models to enhance learning and memory56. They 
linked statins to modulation of signaling pathways in learning, rather than its 
cholesterol-lowering role. Similarly, Wolozin et al. wrote a paper re-assessing the 
role statins play in the therapy of AD from one of prevention to one of reducing 
the progression of the disease. They also postulated that the mechanism behind 
statin’s effects were anti-inflammatory rather than amyloid related57.  
 Some statins like Lovastatin, which is the most lipophilic44, were shown to 
lower cholesterol levels in the brain as well as their restorative functions on 
memory and learning48,58. But in yet another study, Lovastatin was shown to 
increase Aβ levels in female mice but not male mice59, even though it lowered 
plasma cholesterol in both sexes. Thus, preclinical trials testing the purported 
therapeutic benefits of statins on Alzheimer’s disease are frequent, specific, and 
at many times have frustratingly different conclusions. 
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Clinical Trials 
SALSA study 
The Sacramento Area Latino Study on Aging (SALSA) was started in 
1998-1999 as a prospective study of Mexican American individuals sixty years 
old or older from Sacramento, California and the surrounding areas. The study 
objective was to see if there really is an association between statin use, 
dementia, and cognitive impairment without dementia (CIND). It was a very large 
cohort of 1,789 older adults over a 5-year length span. At baseline, 115 
participants had dementia and were thus screened out. The participants were 
called semiannually, and details about their statin use was obtained as well as 
direct inspection of their prescribed medication. They were asked about their 
statin use, dose, and frequency. Their cognitive state was also measured, using 
various evaluations, including the Mini-Mental State Examination60. 
A total of 452 out of 1674 participants without dementia or CIND at the 
start of the study took statins during the five years (27%), and 263 of them took it 
more than 2 years. The lifestyle risk factors were comparable between the 
participants who took statins and those who did not. Over the length of the study, 
130 participants developed dementia or CIND60 (7.7%). After adjusting for 
baseline diabetes, stroke, education level, APOE4 allele, and smoking status 
using the Cox proportional hazard model (statistical survival model), statin use 
resulted in 44% lower rate of dementia/CIND60. 
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Rotterdam Study 
In this study, Haag et al. attempted to test whether the effect of statins on 
serum cholesterol levels followed the same mechanism of action at work in the 
brain. To test this they used statins as well as other cholesterol lowering drugs. In 
addition, they wanted to test the efficacy of hydrophilic versus lipophilic statins to 
determine if there were any noticeable differences in humans61. 
The study took place in Ommoord, a part of Rotterdam in the Netherlands 
and followed a prospective population cohort. The enrollment period was 1990-
1993, for residents aged 55 years or older. They found 10,275 eligible 
participants and after screening they had 6,992 people without dementia at 
baseline for the study.  The follow up was on average 9 years, but extended up 
to 15 years for some participants. The study had a very rigorous follow up, 
including bimonthly updates from municipality records; follow up examinations, 
clinical workups for dementia, and continuously monitoring for diseases.  To 
monitor medication, 99.7% of participants were registered to automated 
pharmacies that recorded their prescription history61. 
The diagnosis of dementia was made using the MMSE and the Geriatric 
Mental State. Those that failed either of those tests underwent the Cambridge 
examination for further testing of mental disorders.  In all, 739 participants 
developed dementia and 582 of them progressed to AD.  Only 30 cases of AD 
came from those who used statins, compared to 546 cases from participants that 
never used any statins. Lastly, the study found that there was no relation with a 
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stronger protective impact of lipophilic statins such as Simvastatin compared with 
hydrophilic statins like Pravastatin. These two were the most frequently used and 
prescribed statins as well61.  
ACT study 
The Adult Changes in Thought cohort study was based in the Seattle, 
Washington area. The participants were all members of the health maintenance 
organization, Group Health Cooperative. Subjects were split into two cohorts; the 
Original cohort was enrolled in 1994-1996 and had 2581 participants while the 
Expansion cohort had 811 participants. The criteria for selection were an age of 
65 or older and a score of 86 or greater on the Cognitive Abilities Screening 
Instrument, an exam testing cognitive function62. 
The hypothesis tested was whether statin therapy that started before any 
clinically relevant signs of AD presented would have a benefit in participants 
younger than 80 years old. Also, because those with the APOE4 allele are more 
susceptible to early onset AD, would the effects of statins help reduce incidence 
of dementia in these individuals. 2,755 participants or 89% of the cohort were 
screened for the APOE4 genotype and 23% of participants actually had the allele 
(though roughly the same percentage were in the statin and non-statin groups)62. 
 Of all participants, 711 had a statin treatment of 5.4 years on average and 
they were younger as well as had higher cognitive function at baseline than non-
statin users. Throughout the 5 years average follow up, 263 people were 
diagnosed with AD or probable AD, with a mean onset age of 82.9 (SD 5.1). The 
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results of this study found that the neuroprotective effect of statins diminished 
with age, being much more effective from ages 65-79, than 80 years old or older. 
The results were obtained through statistical analysis, more specifically Cox 
proportional hazards regression model and 95% confidence interval for risk of 
probable AD for statin users62.  
Statin use had no reduction in AD for older individuals, but the lack of 
association may have been due to a survivor bias. Those that survived past 80 
most likely did not have cardiovascular disease, diabetes, or stroke, which are 
risk factors for AD and thus were probably healthier overall.  Also, since statins 
have many attributed vascular effects1, those without any cerebrovascular or 
cardiovascular problems past 80 years old would have a reduced impact to the 
drug and thus a weakened association62.  
There was also no association between APOE4 allele participants and 
those without the allele. These results are consistent with those in other reports, 
such as the Rotterdam study61. So in summary, this observational study 
suggested that statin use in early old age as a potential therapy to delay the 
neurodegeneration was beneficial at the start of the AD progression but this  
appeared to not prevent or reverse brain damage caused by the deterioration62. 
  
Alzheimer’s Disease Cooperative Study 
The Alzheimer’s Disease Cooperative Study (ADCS) is a randomized 
clinical trial (RCT) conducted at 45 sites across the United States, funded by the 
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National Institute on Aging. Simvastatin was selected to test the hypothesis that 
reducing cholesterol levels could help “reduce the clinical progression in subjects” 
who have normal cholesterol levels63.  The trial was to find evidence that statins 
can decrease the rate of decline on the cognitive portion of the ADAS, a test 
designed to measure disturbances in memory, attention, and other cognitive 
impairments that are considered the core symptoms of AD64.  
 The inclusion criteria included an age of 50 years or older, as well as a 
MMSE score of 12-26 (out of 30). Exclusion criteria included any pre-existing 
neurological or psychological disorders that would interfere with the study, as 
well as those patients who were already on lipid lowering drugs prior to the start 
of the study or if their LDL-C fell below 80mg/dL or triglycerides fell below 500 
mg/dL. Other exclusions included those who already started medication for AD or 
for probable AD/ other neurodegenerative disorders63.  
 The participants were split up into two equal groups by a randomization 
sequence. The two groups were the placebo group or the simvastatin treatment 
group. The trial length was for 18 months, and simvastatin dosage was initially 20 
mg for 6 weeks then increased to 40 mg for the rest of the study. This dosage 
was based on how those with hypercholesterolemia would be prescribed63.  
 Primary and secondary outcomes were based off of the ADAS, and 
additional statistical analysis was used to form usable results. Laboratory testing 
was also conducted on those who consented, including APOE genotyping and 
measurements of lipid levels and C-reactive protein, which is a pro-inflammatory 
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marker released into the bloodstream that is positively correlated with 
cardiovascular risks65.  
 Recruitment lasted from 2002 to 2006, with 406 participants meeting 
inclusion criteria out of 685 screened. They were randomized with an equal 
chance of both groups, and 204 ended up in the simvastatin treatment group and 
202 in the placebo group. Total cholesterol and LDL levels were also significantly 
reduced and HDL levels were significantly raised as well. The presence of the 
APOE4 allele was not a factor in either group and not included in further analysis, 
which further confirms the evidence from the ACT study63. 
 
Figure 11. Simvastatin vs. Placebo treatment on ADAS-cognitive portion 
(adapted from Sano et al., 201163) 
 
 
The effect of treatment on ADAS-Cog score and the primary/secondary 
outcomes did not vary statistically between the two groups during the 18-month 
span, nor did it vary among the various age subgroups. The only statistically 
of the APOE4 allele was not different in the 2 groups
and not associated with the rate of change in the
ADAS-Cog score and therefore not included in the
analysis. The ffect of treatment on the primary out-
come measure is shown in figure 2 and table 2. In the
primary GEE analysis the rate of change in ADAS-
Cog score did not differ between treatment groups
(p! 0.25; 95% CI"0.0462 to 0.1680). The annual
point change was 5.52 points for the placebo group
and 6.28 points for the treatment group. Further,
using a median split we examined those of low and
high age and low and high baseline MMSE score and
Figure 2 Effect of treatment on the primary outcomemeasures
Mean of ADAS-Cog!Alzheimer’s Disease Assessment Scale–cognitive portion total score (A) and change score (B) by treatment and visit. Presented with
95% confidence intervals.
Table 1 Baseline characteristics of the subjects
Variable
Placebo
group (n! 202)
Simvastatin
group (n! 204)
All subjects
(n! 406)
Placebo/simvastatin
difference p value
Age, y, mean" SD 75.1# 9.0 74.0# 9.6 74.6# 9.3 0.2931
Female sex, n (%) 121 (59.9) 120 (58.8) 241 (59.4) 0.8404
Education, y, mean" SD 14.2# 3.3 14.3# 3.2 14.3# 3.2 0.9273
Duration of disease, y 4.23 (2.63) 4.03 (2.58) 4.13 (2.61) 0.3922
Caucasian, n (%) 188 (93.1) 181 (88.7) 369 (90.9) 0.1672
Hispanic/Latino, n (%) 18 (9.0) 6 (3.0) 24 (6.0) 0.0188
APOE #4 carrier, n (%) 100 (55.3) 108 (61.0) 208 (58.1) 0.2853
Total cholesterol, m an" SD 208.8# 28.6 215.0# 32.5 211.9# 30.8 0.1153
Low-density lipoprotein 123.2# 24.4 128.9# 26.4 126.0# 25.1 0.0529
High-density lipoprotein 61.1# 16.7 60.7# 16.2 60.9# 16.4 0.6945
ADAS-Cog score, mean" SD 23.9# 10.5 24.5# 9.7 24.2# 10.1 0.2647
MMSE score, mean" SD 20.7# 4.9 20.0# 4.5 20.4# 4.7 0.0895
ADCS-ADL, mean" SD 68.6# 10.4 67.2# 10.0 67.9# 10.2 0.0414
Dependence scale, mean" SD 4.9# 2.3 5.2# 2.3 5.1# 2.3 0.2432
Neuropsychiatric Inventory, mean" SD 7.8# 8.3 9.2# 10.5 8.5# 9.5 0.6246
Abbreviations: ADAS-Cog ! Alzheimer’s Disease Assessment Scale–cognitive portion; ADCS-ADL ! Alzheimer’s Disease
Cooperative Study Activities of Daily Living; MMSE!Mini-Mental State Examination.
Neurology 77 August 9, 2011 559
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relevant data came in the form of reduced CRP levels in the simvastatin 
treatment group. Therefore this large scale, multi-center RCT does not support 
statin therapy for Alzheimer’s disease63. 
 
DISCUSSION 
 
 The putative effect of the statin family on preventing Alzheimer’s disease 
has generated a vast amount of research (clinical, biomedical and 
epidemiological) into ascertaining whether a causative link can be found. Yet the 
reality of the matter is that the intrinsic properties of statins make it almost 
impossible to create reproducible studies that show similar results in both 
preclinical and clinical trials. 
 Statins are the best drug on the market for treating hypercholesterolemia 
and dyslipidemia. This is due to its very potent ability to not only reduce LDL 
cholesterol and triglyceride levels, but also to increase HDL as well as have very 
mild side effects. It’s effect on the mevalonate pathway to inhibit HMG-CoAR, the 
rate-limiting enzyme, decreases cholesterol production in our body. But when we 
attempt to transfer this lipid lowering ability to treat neurodegenerative disorders 
like dementia and Alzheimer’s disease, we run into many, many roadblocks.  
  
First is simply that we cannot assume statins function the same way in 
neuroprotection as they do in fat metabolism. This is further complicated by the 
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many pleiotropic effects attributable to statins, both cellularly and systemically 
(Figure 12) 34. The first is its direct action on brain cholesterol by crossing the 
blood brain barrier. Once, it was thought that only lipophilic statins could cross 
the barrier and exert its effects. Now we know that statins in the lactone form are 
also transferred across the BBB via diffusion, and that other hydrophilic statins 
also exert a neuronal impact33.  
Statins also have a very important impact on the inflammatory response. 
They suppress leukocyte adhesion by hindering the binding of cell adhesion 
molecules, thus depressing the inflammation in the brain and reducing brain 
injury. In addition to its anti-inflammatory properties, it is also anti-apoptotic by 
influencing cellular signaling and blocking amyloid-induced neuronal death. 
Statins also have an anti-oxidant effect as they block the effects of ROS caused 
by amyloid plaque formation and hyperphosphorylation of tau34.  
Only recently has research started to delve into these pleiotropic effects 
as they relate to Alzheimer’s disease. It is essential to understand the 
mechanism of action of these pathways because they shed light on how a statin 
treatment would affect patients on a gross level. Currently, no preclinical study 
has been able to fully integrate these other effects into their experiments, rather 
focusing on studying how statin use affects cholesterol balance in the brain and 
thus alters amyloid plaque formation.  
Another confounding variable during these preclinical trials is the use of 
various statins, rather than focusing on one or two of the more potent forms. By 
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utilizing this wide range, each study will of course have differing results. This is 
especially worrisome in biomedical experiments because individual molecular 
levels are measured, such as amyloid formation, cholesterol levels, C-reactive 
protein (CRP) levels. Although the members of the statin family may have very 
similar abilities to lower total serum cholesterol, this may or may not translate to 
all pathways in which the drugs are involved.    
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Clinical trials have also had difficulty reaching a consensus on whether 
statins are an effective therapy. This is due to many variables in the study design 
itself. The first and foremost is clearly defining what the study is hoping to 
achieve. This is because some studies test the hypothesis that statins slow the 
progression of AD, while others test whether statins can help reverse the 
symptoms of dementia or halt any further cognitive impairment. These two 
examples aim to show that statins either are a protective or preventative. Both 
experiments test drastically different mechanisms of action, which can account 
for their differing results.  
Secondly, the age of the participants and when the drug regiment is 
initiated is very important. As discussed earlier, the need for biomarkers to 
diagnose AD early on is crucial, as multiple pathophysiological processes are at 
work for years before any sort of clinical signs and symptoms show. Thus it may 
be more important for clinical trials to become more longitudinal, lasting for more 
than ten year. As shown in the preclinical study by Tong et al, statins had a 
greater effect when treatment lasted for a longer period of time and this study 
can be applicable to clinical trials as well. If the AD effect of statin therapy is 
indeed a protective mechanism, it may take months to years before the benefits 
can be measured, and it these protective measures may help safeguard the brain 
against the deleterious progression of AD.  
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In order to assure administration of treatment before AD develops, it is 
important to start years before the earliest clinical signs of MCI, somewhere 
around 50 years of age (Like the ADCS study, though it lasted only 18 months). 
This is relevant when examined in the context of the ACT study results. Their 
experiment showed that statin use was more beneficial when given to younger 
participants as opposed to older participants.  
Lastly, it is important to see if the protective effects extend to all 
participants within a clinical trial or if they greatly favor those who already have 
hypercholesterolemia. This is important because high cholesterol and 
atherosclerosis are significant risk factors for AD, and statin treatment may just 
reduce the atherosclerotic plaque formation. This is turn may lower their chances 
of being diagnosed with AD, but it doesn’t prove a direct correlation. A study 
comparing those with hypercholesterolemia and those without is a great next 
step in understanding the mechanism of action at work. 
 
 
In summary, the pleiotropic effect of statins are very widespread and 
represent a very complex problem for researchers (Figure 12). The question 
should not be whether or not statins are preventative against AD, but rather how 
they affect AD’s disease progression mechanistically. Only through direct study 
of statin’s other bodily effects, both regionally within the neuronal environment as 
well as globally throughout the body, can we begin to understand how this potent 
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molecule behaves. Preclinical studies about the many effects of statins may even 
open up exploration of an entirely new pathway to treat Alzheimer’s disease. 
Thus it is this study’s recommendation that statins be studied with an aim as to 
how they protect the brain from disease and when the optimal time to initiate 
treatment would be.  
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